Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Hot Topics of the Day|PHGKB
Search PHGKB:

08/10/2022

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Sign up MyPHGKB to receive the daily hot topic email alert.

Search Archive:
Archived Hot Topics of the Day By Date

Distinguishing features of Long COVID identified through immune profiling
J Klein et al, MEDRXIV, August 10, 2022

SARS-CoV-2 hybrid immunity: silver bullet or silver lining?
Suryawanshi Rahul et al. Nature reviews. Immunology 2022 8

Hybrid immunity occurs in those who have been both infected with and vaccinated against SARS-CoV-2. But how well does such hybrid immunity protect against the virus and its emerging variants? Several studies suggest that hybrid immunity confers more effective cross-variant neutralization than a natural infection alone (Fig. 1a,c). Vaccination after infection with the SARS-CoV-2 ancestral Wuhan-Hu-1 strain or with Alpha, Delta and Beta variants increases the number of SARS-CoV-2 memory T cells and B cells by more than an order of magnitude by recruiting new B cell clones into the memory pool and expanding persistent clones.(

The mechanism of RNA capping by SARS-CoV-2.
Park Gina J et al. Nature 2022 8

Long-COVID treatments: why the world is still waiting After a slow start, researchers are beginning to test ways to combat the lasting symptoms of the disease.
H Ledford, Nature, August 9, 2022

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine
G Deliyannis et al, MEDRXIV, August 9, 2022

Clinical effectiveness of SARS-CoV-2 booster vaccine against Omicron infection in residents and staff of Long-Term Care Facilities: a prospective cohort study (VIVALDI)
O Stirrup et al, MEDRXIV, August 9, 2022

Metabolomic and gut microbiome profiles across the spectrum of community-based COVID and non-COVID disease: A COVID-19 Biobank study.
MF Osterdahl et al, MEDRXIV, August 9, 2022

Persistent Presence of Spike protein and Viral RNA in the Circulation of Individuals with Post-Acute Sequelae of COVID-19
V Craddock et al, MEDRXIV, August 9, 2022

Adjusted booster schedules disperse age-dependent differences in antibody titers benefitting risk populations - Update to: Age-dependent Immune Response to the BioNTech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination
L Muller et al, MEDRXIV, August 9, 2022

Measuring Lipoprotein(a) in Clinical Practice to Reduce the Burden of Cardiovascular Disease? Still Work in Progress.
J Osei et al, CDC Blog Post, August 9, 2022 Brand

A recent review suggested that the use of lipoprotein (Lp) (a) measurement in clinical practice may have clinical and economic benefits for patients, healthcare systems, and society as a whole. However, widespread adoption of Lp(a) measurement in the general population has been hindered by limited treatment options targeting Lp(a) reduction.

Interactive exploration of a global clinical network from a large breast cancer cohort
N Sella et al, NPJ Diital Medicine, August 10, 2022

Despite unprecedented amount of information now available in medical records, health data remain underexploited due to their heterogeneity and complexity. Simple charts and hypothesis-driven statistics can no longer apprehend the content of information-rich clinical data. There is, therefore, a clear need for powerful interactive visualization tools enabling medical practitioners to perceive the patterns and insights gained by state-of-the-art machine learning algorithms. Here, we report an interactive graphical interface for use as the front end of a machine learning causal inference server (MIIC), to facilitate the visualization and comprehension by clinicians of relationships between clinically relevant variables.

Leveraging reimbursement strategies to guide value-based adoption and utilization of medical AI
KP Venkatesh et al, NPJ Digital Medicine, August 10, 2022

With the increasing number of FDA-approved artificial intelligence (AI) systems, the financing of these technologies has become a primary gatekeeper to mass clinical adoption. Reimbursement models adapted for current payment schemes, including per-use rates, are feasible for early AI products. A successful reimbursement strategy will align interests across stakeholders to guide value-based and cost-effective improvements to care.


Disclaimer: Articles listed in Hot Topics of the Day are selected by the CDC Office of Genomics and Precision Public Health to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP